# Junta clínica — PT-pseudo_11fe9c6ca833 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_11fe9c6ca833",
  "pid": "PT-pseudo_11fe9c6ca833",
  "task": 1,
  "psa": 190.0,
  "age": 66,
  "months": 2,
  "pirads": "5",
  "psad": 4.097,
  "psav": 41.57,
  "psap": 125.1,
  "vol": 46.38,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.9718793,
  "medhx": "Hypertension, Coronary artery disease",
  "meds": "valsartan, lisinopril, metoprolol, aspirin 80 mg",
  "notes": "PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.",
  "pmhx": [
    "Hypertension",
    "Coronary artery disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "61 kg",
    "height": "167 cm",
    "bmi": "21.9",
    "bp": "125/89 mmHg",
    "hr": "77 bpm",
    "smoking": "Ex-smoker (10 pack-yr, quit 2022)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "02 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer."
    },
    {
      "s": "History",
      "t": "A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses."
    }
  ],
  "occupation": "civil engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "4 units / week",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 14/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_11fe9c6ca833
Task: 1

Encounter: Urology - outpatient on 02 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 190.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 4.097 ng/mL²
  - PSA velocity: 41.57 ng/mL/yr
  - Prior PSA: 125.1 ng/mL
  - Prostate volume: 46.38 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9718793 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease
  - Problem list / PMHx: Hypertension, Coronary artery disease
  - Current medication: valsartan, lisinopril, metoprolol, aspirin 80 mg
  - Allergies: NKA
  - Additional notes: PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.

Vitals: weight 61 kg, height 167 cm, BMI 21.9, BP 125/89 mmHg, HR 77 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2022).

Chief complaint: Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer.

History: A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time.

Physical examination: DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses.

Patient info: civil engineer; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Tennis 2x/week; IPSS score: 14/35 (moderate LUTS).

Recent other appointments: Radiology — chest X-ray (routine).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.36
  uncertainty  +/- 0.16 epistemic (95% band 0.05-0.68); among patients I cannot tell apart the outcome was 0.94 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 2 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 66 (2% of my signal; from age) · DRE = Nodus (10% of my signal; from dre_suspicious) · PSA = 190 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 46.38 mL (1% of my signal; from log_vol, vol) · PSA density = 4.097 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.97 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PSA = 190 ng/mL
  important  prior biopsy = Positive
  noted      age = 66 · DRE = Nodus · prostate volume = 46.38 mL · PSA density = 4.097 · PI-RADS = 5 · comorbidity = 2 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — the rule matched the reading urologist in only 5 of 6 labelled cases

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 48 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 0.72: PI-RADS 5, PSA 160.0, PSAD 2.635, age 63, DRE Abnormal -> DEFER (clear). He wrote: "Start treating the patent. It does not make sense to not treat this man initially."
  2. distance 0.78: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."
  3. distance 1.33: PI-RADS 5, PSA 187.0, PSAD 3.26, age 75, DRE Nodus -> BIOPSY (clear). He wrote: "Very High PSA. Most likely metastatic"

PRECEDENT: DEFER (weighted vote 0.23 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   prior biopsy = Positive · PSA = 190 ng/mL · PI-RADS = 5
  noted      age = 66 · DRE = Nodus · prostate volume = 46.38 mL · PSA density = 4.097 · comorbidity = 2 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   prior biopsy = Positive · PI-RADS = 5
  important  age = 66 · PSA = 190 ng/mL
  noted      family history = not opened (0 of 91) · DRE = Nodus · prostate volume = 46.38 mL · PSA density = 4.097 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses the risk-adapted matrix table linking PI-RADS score and PSA density categories to the decision to perform a biopsy. It states, "This risk-adapted matrix table may guide the decision to perform a biopsy." For this patient, the guideline requires assessing the PI-RADS score and PSA density against the defined risk categories to guide the decision.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your bid of NO BIOPSY is based on the 'prior biopsy = Positive' being decisive, whereas the guideline treats this as context. The guideline requires assessing the PI-RADS score and PSA density against the risk categories to guide the decision. The guideline needs the PI-RADS score and PSA density, which no panel variable represents.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: Positive means the guideline suggests assessing the PI-RADS score and PSA density against the risk categories to guide the decision.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline requires assessing the PSA density against the risk categories to guide the decision.
laboratory_results - the laboratory results: the guideline requires assessing the PSA density against the risk categories to guide the decision.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on whether the PI-RADS score and PSA density, as required by the EAU guideline, override the prior positive biopsy status.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone, extraprostatic extension, and comparison against an earlier study inform the decision?
  psa_trend (get_psa_trend) -> Does the PSA trend inform the decision based on the risk-adapted matrix table?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy, surveillance protocol, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What should be done given the PSA trend?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "What should be done given the PI-RADS score of 5 and PSA density of 4.097?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI of the Prostate
Examination Date: 28 January 2025
Does the lesion size and zone, extraprostatic extension, and comparison against an earlier study inform the decision?
The lesion is described as "sharply demarcated, profoundly hypointense area spanning roughly 28 x 22 x 20 mm within the left peripheral zone at the base and mid-gland." No extraprostatic extension or seminal vesicle invasion is evident. Comparison was prompted by a history of a positive biopsy.

psa_trend
Does the PSA trend inform the decision based on the risk-adapted matrix table?
The PSA trend shows a rise from 15.3 ng/mL (Dec 2023) to 190.0 ng/mL (Feb 2025), with a value of 19.1 ng/mL in Sep 2024.

previous_notes
What is the management context regarding the prior biopsy, surveillance protocol, and planned treatment?
The management context is a re-evaluation following a positive prior biopsy, with the current presentation being a PSA of 190.0 ng/mL.

WHAT I DID NOT OPEN
laboratory_results. I left this closed because the required variables for the EAU guideline assessment (PI-RADS and PSA density) were already present in the structured panel, and the trend/imaging data were retrieved.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 and PSA density 4.097, as required by the EAU guideline assessment.
Rapid and significant PSA velocity (41.57 ng/mL/yr) indicated by the PSA trend.

AGAINST sampling this patient now
Prior biopsy was positive, which Expert-Cohort suggests leads to deferral based on the criterion.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (clear). Last value 190.00 ng/mL over 4 points spanning 14 months; velocity +141.74 ng/mL per year; doubling time about 3 months.
PROJECTION at 6 months: 720.4 ng/mL, conformal 95% band 206.7-2511.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  important  PSA = 190 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: clear — the conformal band clears the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.35
  uncertainty  +/- 0.13 epistemic (95% band 0.09-0.61), of which 0.01 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 190 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 46.38 mL (4% of my signal; from log_vol, vol) · PSA density = 4.097 (0% of my signal; from psad_calc) · comorbidity = 2 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.36  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.35  ('supports' tier, fusion_nolab; weight 3.0)
  EXPERT-EXPERIENCE  DEFER, p(biopsy)=0.23  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule psa_ge_20; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:DEC E2:—            -> decisive
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:— E2:—                    -> not_used (raised from noted by the board)
  age          66                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Nodus                        E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          190 ng/mL                    E1:not E3:not cohort:DEC library:DEC E2:IMP          -> important
  vol          46.38 mL                     E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         4.097                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.97                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:DEC E2:—            -> decisive
  comorbidity  2 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) appear to answer the moderator's questions, as the trace model listed these documents, and none were left unopened.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of NO BIOPSY. Specifically, the PSA trend showing a rise from 15.3 ng/mL to 190.0 ng/mL, with a value of 19.1 ng/mL in Sep 2024, aligns with the cohort criterion that fired the panel decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What should be done given the PSA trend? The PSA trend shows a rise from 15.3 ng/mL (Dec 2023) to 190.0 ng/mL (Feb 2025), with a value of 19.1 ng/mL in Sep 2024.

WHAT CARRIES WEIGHT, AND WHY
psa: important: 190 ng/mL, because the panel marked this as important, and the PSA trend supports the cohort criterion. pirads: decisive: 5, because the panel marked this as decisive, and the EAU guideline requires assessing this score. I would not move these levels as they align with the panel's decision based on the retrieved data. My confidence in the record as it stands is clear.

MY SUGGESTION TO THE CHAIR
I suggest deferral, as the panel protocol is clear and the retrieved data supports the cohort criterion that led to this decision.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

66y male, PSA 190 ng/mL, PSAD 4.1, PI-RADS 5, prior positive biopsy. High PSA and PI-RADS 5 suggest established disease, making further biopsy inappropriate. The prior biopsy grade is not recorded, but the current findings dictate staging and treatment planning.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
